RosTrace

Tag: PatientOutcomes

Robin Hayes

Experimental ALS Therapy Spurs Unprecedented Recoveries in Early Trials

In a remarkable departure from the typical expectations of neurodegenerative disease trials, an experimental therapy targeting a rare genetic form of amyotrophic lateral sclerosis (ALS) has yielded unprecedented functional recoveries in some patients. The therapeutic agent, ulefnersen—formerly known as jacifusen—was developed by Columbia University neurologist Dr. Neil Shneider in collaboration with Ionis Pharmaceuticals. Data published online in The Lancet reveal that two of the 12 patients treated for juvenile-onset FUS-mutant ALS experienced dramatic improvements, including the restoration of walking ability and respiratory independence, while another asymptomatic carrier has yet to develop disease signs after three years of continuous treatment.

· 5 min read

Robin Hayes

New Biomarker Predicts Multiple Sclerosis Progression, Offering Hope for Better Treatment Strategies

Researchers at the University of Turku have identified a novel biomarker that may revolutionize how clinicians assess the progression and severity of multiple sclerosis (MS), a chronic autoimmune disease of the central nervous system. The groundbreaking study, published in Nature Medicine, offers promising new directions for both targeted treatment and faster development of therapeutic drugs—particularly for progressive MS, which remains one of the most challenging forms of the disease to treat.

· 3 min read